Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Elizabeth Gialde"'
Autor:
Tony Sun, Kathy Goggin, Philip Jones, Carole Decker, Elizabeth Gialde, John A. Spertus, Dave deBronkart, Delwyn Catley, Katie Jaschke, Adnan K. Chhatriwalla
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 12
Background: Drug-eluting stents reduce the risk of restenosis in patients undergoing percutaneous coronary intervention, but their use necessitates prolonged dual antiplatelet therapy, which increases costs and bleeding risk, and which may delay elec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9eec9806a497362e521675e2744d5499
https://doi.org/10.1161/circoutcomes.118.005139
https://doi.org/10.1161/circoutcomes.118.005139
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 10
Background: Alteplase does not uniformly benefit patients with acute ischemic stroke (AIS). Variable times since symptom onset, age, comorbidities and symptom severity add much uncertainty to physicians’ ability to knowledgeably individualize clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84891ed7dfb58e55fab8807a0467f843
https://doi.org/10.1161/circoutcomes.10.suppl_3.222
https://doi.org/10.1161/circoutcomes.10.suppl_3.222
Autor:
Marilyn M. Rymer, Elizabeth Gialde, Jeffrey L. Saver, David M. Kent, Er Chen, Eric M. Cheng, Debbie Summers, Emily Chhatriwalla, Brian Garavalia, Carole Decker, Miriam E. Quinlan, John A. Spertus
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 8
Background— National guidelines endorse recombinant tissue-type plasminogen activator (r-tPA) in eligible patients with acute ischemic stroke to improve patients’ functional recovery. However, 23% to 40% of ideal candidates with acute ischemic st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce0b5f34ed898e3f40a96e10ddf85f1f
https://doi.org/10.1161/circoutcomes.115.002003
https://doi.org/10.1161/circoutcomes.115.002003
Autor:
Linda Garavalia, Carole Decker, Brian Garavalia, John A. Spertus, Adnan K. Chhatriwalla, Robert W. Yeh, Elizabeth Gialde
Publikováno v:
American heart journal. 178
Background The foundation of precision medicine is the ability to tailor therapy based upon the expected risks and benefits of treatment for each individual patient. In a prior study, we implemented a software platform, e PRISM, to execute validated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c34d80de55b9687dd82ce6d47133cb4d
https://pubmed.ncbi.nlm.nih.gov/27502867
https://pubmed.ncbi.nlm.nih.gov/27502867
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 8
Background: Cardiac arrest (CA) claims an estimated 300,000 lives in America each year even with cardio-pulmonary resuscitation (CPR) efforts. Additionally, of the patients who survive CPR and are discharged, many have suffered anoxic brain injury. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0c06b17a09a8f36372e263e08cd00e4
https://doi.org/10.1161/circoutcomes.8.suppl_2.289
https://doi.org/10.1161/circoutcomes.8.suppl_2.289
Autor:
Carole Decker, Mark W Poirier, Emily Chhatriwalla, Elizabeth Gialde, John A Spertus, Tara M Mayhugh, Karly M Schleicher, Joan M McDowd
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 7
Background: During the early phase of ischemic stroke (IS), thrombolytic (recombinant tissue plasminogen activator; rt-PA) therapy has been shown to effectively reverse symptoms and improve outcomes. However, serious bleeding can occur, which has dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e83c089292f2ddad06b016d7c81801c0
https://doi.org/10.1161/circoutcomes.7.suppl_1.277
https://doi.org/10.1161/circoutcomes.7.suppl_1.277
Autor:
Carole Decker, Emily Chhatriwalla, Debbie Summers, Marilyn M. Rymer, Brian Garavalia, John A. Spertus, Elizabeth Gialde
Publikováno v:
Stroke. 45
Study Objectives: Multiple guidelines endorse recombinant tissue plasminogen activator (rt-PA) in eligible patients with acute ischemic stroke (AIS), but only 4-6% of patients are treated. Clinician doubts about treatment benefits or operational barr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cef7f13a55e695b371e5d82343ea492
https://doi.org/10.1161/str.45.suppl_1.ns19
https://doi.org/10.1161/str.45.suppl_1.ns19
Autor:
Carole J Decker, Emily Chhatriwalla, Brian Garavalia, John A Spertus, Er Chen, Elizabeth Gialde
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 6
Background: Explaining the risks and benefits of recombinant tissue plasminogen activator (rt-PA) occurs in a hurried conversation in the emergency department and may not be fully grasped by patients and their caregivers. Risk models describing the h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f24b363d5fc1e042a839aa482abd9c84
https://doi.org/10.1161/circoutcomes.6.suppl_1.a215
https://doi.org/10.1161/circoutcomes.6.suppl_1.a215
Autor:
Eric Cheng, Miriam Ayad, Elizabeth Gialde, Emily Chhatriwalla, John A Spertus, Marilyn Rymer, Debbie Summers, Jeffrey Saver, Carole Decker
Publikováno v:
Stroke. 44
Background: Explaining the benefits and risks of tissue plasminogen activator (tPA) is typically done through hurried verbal explanations in the emergency department, but it may not be understood by patients and caregivers. However, spending more tim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eb9da1a4b2f0b127c911c88227cf464
https://doi.org/10.1161/str.44.suppl_1.atp234
https://doi.org/10.1161/str.44.suppl_1.atp234